The emergence of antibody-drug conjugates (ADC) has ushered in a new era of precision therapy in lung cancer treatment. By conjugating highly selective monoclonal antibodies with highly potent cytotoxic payloads, ADC achieve precise targeting and killing of tumor cells while reducing systemic toxicity, facilitated by the bystander effect and other mechanisms. This article systematically reviews the latest advances in ADC for both non-small cell lung cancer and small cell lung cancer, and summarizes the latest data from key clinical trials,including the DESTINY-Lung series, TROPION-Lung series, and IDeate-Lung01, with a focus on the clinical efficacy of ADC targeting different key targets. Furthermore, this review analyzes the potential mechanisms of resistance to ADC and treatment-related adverse events, and summarizes the corresponding management strategies, providing a reference for the clinical application of ADC in lung cancer therapy.